検索結果 - Meredith Libeg

  • 検索結果 1 - 3 結果 / 3
結果の絞り込み
  1. 1
    FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy

    FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy 著者: Dickran Kazandjian, Daniel L. Suzman, Gideon M. Blumenthal, Sirisha L. Mushti, Kun He, Meredith Libeg, Patricia Keegan, Richard Pazdur

    出版事項 2016
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  2. 2
    Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy

    Benefit-Risk Summary of Nivolumab for Patients With Metastatic Squamous Cell Lung Cancer After Platinum-Based Chemotherapy 著者: Dickran Kazandjian, Sean Khozin, Gideon M. Blumenthal, Lijun Zhang, Shenghui Tang, Meredith Libeg, Paul G. Kluetz, Rajeshwari Sridhara, Patricia Keegan, Richard Pazdur

    出版事項 2015
    全文の入手 全文の入手
    Artigo
    お気に入りに追加
    保存先:
  3. 3
    FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma

    FDA Approval of Nivolumab for the First-Line Treatment of Patients with BRAFV600 Wild-Type Unresectable or Metastatic Melanoma 著者: Julia A. Beaver, Marc R. Theoret, Sirisha L. Mushti, Kun He, Meredith Libeg, Kirsten B. Goldberg, Rajeshwari Sridhara, Amy E. McKee, Patricia Keegan, Richard Pazdur

    出版事項 2017
    全文の入手
    Artigo
    お気に入りに追加
    保存先:

検索ツール: